CONNECTING Healthcare EXPERTISE

THE CLINICIAN EXCHANGE is a virtual exchange designed to pair specific clinical skillsets with specific industry initiatives.

EXCHANGE YOUR EXPERTISE

Learn how you can unlock the power of your expertise and experience to impact the healthcare industry in ways never before imagined

REGISTER NOWLEARN MORE

EXTEND, EXCEL…EXPLORE THE EXCHANGE

Learn how you can cost-effectively multiply your sales, education and R&D resources in an instant

REGISTER NOWLEARN MORE

COMMUNITY PORTAL

IN THE NEWS

CLINICIAN NEWS

Provided by: Medscape

Durvalumab in Stage III Lung Cancer: 'An Important Advance'

Published: Tue, 17 Oct 2017 12:53:12 EDT
New data from the PACIFIC study show that durvalumab is well tolerated, with no impact on quality of life; its improvement of PFS is an 'important advance,' says expert.
Medscape Medical News

UK Bans Super-Sized Chocolate Bars from Hospital Shops

Published: Tue, 17 Oct 2017 12:36:11 EDT
Hospital shops are to be banned from stocking 'super-sized' chocolate bars by NHS England.
WebMD Health News

Jamie Oliver's Sugary Drinks Levy 'Cut Sales'

Published: Tue, 17 Oct 2017 12:20:45 EDT
A 'sugar tax' imposed on sugar-sweetened drinks in a UK restaurant chain led to a fall in sales and more people choosing healthier alternatives, an investigation has found.
WebMD Health News
Displaying results 4-6 (of 20)
 1 - 2 - 3 - 4 - 5 - 6 - 7 

HEALTHCARE SUPPLIER NEWS

Sanofi cancer executive jumps ship to Silicon Therapeutics

Published: Tue, 17 Oct 2017 09:22:07 +0000
Sanofi veteran Christopher Winter has been appointed as the new chief of R&D at drug discovery biotech Silicon, becoming the latest in an increasingly long line of Big Pharma executives to join the early-stage life science stream.

Biotech builder Cydan gets cash injection for genetic disorders

Published: Tue, 17 Oct 2017 09:04:03 +0000
Drug accelerator Cydan has gained a $34 million injection as it eyes deeper inroads into rare diseases for its second fund. The company, which has spun out several biotechs, is looking to repeat its successes by using the cash boost to seek out preclinical rare disease candidates.

Pfizer’s son of Xalkori impresses in phase 2 NSCLC trial

Published: Mon, 16 Oct 2017 13:33:38 +0000
Pfizer has posted a full look at data from a phase 2 trial of lorlatinib in patients with advanced non-small cell lung cancer (NSCLC). The ALK inhibitor triggered responses in a significant minority of heavily pretreated patients, suggesting it can play a role in NSCLC treatment pathways.
Displaying results 4-6 (of 25)
 1 - 2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 

HAVE A QUESTION?

 Security code

Clinician Owned and Veteran Owned

copyright 2017 THE CLINICIAN EXCHANGE. Privacy Policy
Top